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ABCA1, a cholesterol transporter expressed in the brain, has
been shown recently to be required to maintain normal apoE levels
and lipidation in the central nervous system. In addition, ABCA1
has been reported to modulate -amyloid (A) production in vitro.
These observations raise the possibility that ABCA1may play a role
in the pathogenesis of Alzheimer disease. Here we report that the
deficiency of ABCA1 does not affect soluble or guanidine-extract-
able A levels in Tg-SwDI/B or amyloid precursor protein/preseni-
lin 1 (APP/PS1) mice, but rather is associated with a dramatic
reduction in soluble apoE levels in brain. Although this reduction in
apoE was expected to reduce the amyloid burden in vivo, we
observed that the parenchymal and vascular amyloid load was
increased in Tg-SwDI/B animals and was not diminished in APP/
PS1 mice. Furthermore, we observed an increase in the proportion
of apoE retained in the insoluble fraction, particularly in the APP/
PS1 model. These data suggested that ABCA1-mediated effects on
apoE levels and lipidation influenced amyloidogenesis in vivo.
Alzheimer disease (AD)8 is themost common cause of senile demen-
tia and currently affects 40% of the population over 80 years of age.
Clinically, AD is characterized by severe impairments in memory and
executive cortical functions as well as difficulties in language, calcula-
tion, visuospatial perception, behavior, and judgment (1). Characteristic
neuropathological hallmarks of AD include intraneuronal fibrillary tan-
gles composed of hyperphosphorylated tau protein and amyloid depos-
its that are composed largely of A peptides, apolipoprotein E (apoE),
lipids, and other proteins that accumulate in the neural parenchyma and
the cerebrovasculature (2, 3). A peptides are a heterogeneous group of
peptides 39–43 amino acids in length that are proteolytically cleaved
from amyloid precursor protein (APP) by - and -secretases (4, 5).
A40 and A42 are the main A species in the brain. A42 is less
soluble and is present in all types of senile plaques, whereas A40 is the
major species deposited in cerebral blood vessels (4–7).
Most affected individuals have late onset AD that typically manifests
after 70 years of age. However, a number of families develop the disease
in their 4th or 5th decades (8, 9). The cases of familial AD result from
mutationswithinAPPor secretase components (8, 10). For example, the
Swedishmutation (K670M/N671L) increases the amount of A peptide
that is generated fromAPP (11, 12).OtherAPPmutations, including the
Dutch (E693D) and Iowa (Q694N)mutations, alter the charge of the A
peptide and result in amyloid deposition predominantly in the cerebral
blood vessels rather than in the parenchyma (13–16). In addition to
mutations in APP, over 100 different mutations have been identified in
presenilin-1 alone (17). However, less than 5% of the overall clinical
burden of AD is caused by mutations in APP and presenilins combined.
To date, the only well established risk factor for late-onset AD is apoE
(18, 19). In the human population, apoE exists as three major alleles
(apoE2, apoE3, and apoE4), and inheritance of an apoE4 allele increases
the risk of developingAD at an earlier age, whereas inheritance of apoE2
delays the age of onset of AD (20–22). How apoE functions in the
pathogenesis of AD is a subject of intense investigation. ApoE is a com-
ponent of several lipoprotein subclasses, including very low density
lipoprotein andHDL particles in the peripheral circulation, where apoE
acts to mediate their uptake by apoE receptors (23, 24). In the central
nervous system, apoE is synthesized and secreted by astrocytes and
microglia and serves as the major cholesterol carrier in the brain and
cerebrospinal fluid (25–29). In the brain, apoE expression is increased
under conditions of chronic or acute neuronal damage, where it is
believed to acquire lipids from damaged neuronal processes and rede-
liver these lipids to neurons during reinnervation (30–33).
In addition to lipid trafficking, apoE also plays a major role in A
metabolism. ApoE binds avidly to A peptides and is found within
amyloid plaques (34, 35). ApoE is believed to play a major role in the
conversion of A peptides from soluble to fibrillar form, based on the
observation that apoE-deficient animals are unable to form mature
amyloid in vivo (36–40). Although A is deposited in the brains of
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apoE-deficient mice, the deposits do not contain structural amyloid as
defined by the ability to bind thioflavine or Congo Red dyes (36–40).
Furthermore, amyloid deposition is similar in distribution but less
extensive in apoE heterozygous mice, suggesting a dose-dependent
effect of apoE level on amyloid formation (41). Therefore, factors that
affect apoE abundancemay also affect amyloid deposition and influence
the onset or progression of AD.
The ATP-binding cassette transporter ABCA1 has recently been
shown to modulate apoE levels in the brain, cerebrospinal fluid, and
plasma (42, 43). In peripheral tissues, the primary biochemical function
of ABCA1 is to transport cholesterol and phospholipids from the
plasma membrane to lipid-free apoAI, a reaction that constitutes the
first step in HDL biogenesis (44). The pre--HDL particles generated
from this reaction circulate in the bloodstream and acquire additional
lipids to formmature HDL particles. ABCA1-dependent lipid transport
to apoAI is the major pathway by which excess sterols from peripheral
tissues are transported to the liver where they are converted into bile
acids and excreted from the body.Mutation of oneABCA1 allele causes
familial hypoalphalipoproteinemia, a mild disorder of peripheral lipid
metabolism characterized by reduced plasmaHDL levels (45).Mutation
of both alleles of ABCA1 results in Tangier disease, which is character-
ized by a nearly complete absence of plasma HDL, deposition of intra-
cellular cholesterol esters, and an increased risk of cardiovascular
disease (45–47).
In addition to high expression in liver and macrophages, ABCA1 is
also abundant in the central nervous system (48–51). ABCA1 is
expressed in neurons, astrocytes, and microglia and is transcriptionally
induced by liver X receptor and retinoic X receptor agonists, similar to
ABCA1 regulation in noncentral nervous system cells (48–51).
Although the functions of ABCA1 in the brain are not completely
understood, it is likely that ABCA1 participates in the regulation of lipid
trafficking among the various cell types within the brain.We and others
have shown that ABCA1 mediates cholesterol efflux to apoE and regu-
lates the secretion of apoE from astrocytes and microglia (42, 43). Lack
of ABCA1 results in accumulation of lipids in cultured glia, impaired
secretion of glia-derived apoE, and a drastic reduction of apoE levels in
the brain, particularly in the hippocampus and striatum (42, 43). Fur-
thermore, ABCA1-deficient glia exhibit impaired cholesterol efflux to
apoE (42), and the low level of apoE that remains in the cerebrospinal
fluid and brains of ABCA1-deficient mice is poorly lipidated (43). The
observation that ABCA1 is a critical modulator of apoE abundance and
lipidation in the central nervous system raises the possibility that
ABCA1may influence the onset or progression ofAD through its effects
on apoE.
Many previous studies have shown that intracellular cholesterol lev-
els modify the cleavage of APP by secretases (52–57). Low intracellular
cholesterol favors the non-amyloidogenic cleavage of APP by -secre-
tase and leads to decreased A generation, whereas high intracellular
cholesterol favors APP cleavage by - and -secretases and thereby
increases A production (52–57). In vitro, two recent studies showed
that increased ABCA1 reduced the generation of A peptides derived
from human APP (51, 58), and a third study found that excess ABCA1
increased the generation of endogenous rodent A (59). The lack of
consensus among these studies underscores the need to evaluate the
role of ABCA1 on A levels in a physiologically relevant in vivo setting.
Recently, Koldamova et al. (60) demonstrated that A40 and A42
levels were significantly reduced in APP23 mice treated with the liver X
receptor ligand TO901317, concomitant with increased ABCA1
expression in neurons. Although these results support a role for neuro-
nal ABCA1 inA production in vivo, TO901317 induces the expression
of several other genes in addition to ABCA1. For example, TO901317
has been reported to stimulate the expression of apoE in glial cell lines
and in mice (61), although other groups have not observed significant
increases in apoE expression in response to TO901317 (60, 62).
TO901317 also induces othermembers of theABC-cassette transporter
superfamily that may also participate in central nervous system lipid
homeostasis.
BecauseABCA1 is expressed in several cell types in the brain, ABCA1
may play multiple roles in the pathogenesis of AD. For example, neuro-
nal ABCA1 may play a prominent role in regulating intraneuronal cho-
lesterol content, thereby influencing the production of A peptides.
From this perspective, the deficiency of ABCA1 would be predicted to
increase intraneuronal lipids and lead to elevated A levels. On the
other hand, glial ABCA1 is crucial for normal apoE levels and lipidation
(42, 43). Because apoE is required for amyloid deposition (36–39), and
deficiency of ABCA1 results in a 70% reduction in apoE levels, the
absence of ABCA1 would be predicted to decrease amyloid deposition
in vivo. Therefore, the lack of ABCA1 could theoretically result in oppo-
site outcomes in amyloid deposition depending uponwhether themajor
role of ABCA1 is on A production or A clearance and deposition via
apoE. Determining whether deficiency of ABCA1 increases, decreases,
or has no net effect on A and amyloid burden will therefore require
investigating the effect of ABCA1 deficiency on A and amyloid depo-
sition in vivo where the physiological interactions among neurons and
glia during the process of amyloid deposition are preserved.
We therefore crossed ABCA1-deficient mice to two independent
murine models of AD to determine the impact of ABCA1 on amyloid
burden, A levels, and apoE levels in vivo. Here we report that elimina-
tion of ABCA1 has no measurable impact on the steady-state levels of
soluble or guanidine-extractable human A when crossed to either
model, and no effect on endogenous murine A levels in the parental
ABCA1-deficient mice. Lack of ABCA1 did result in the expected
reduction in soluble apoE levels, consistent with previous results (42,
43). Because apoE is required for amyloid deposition, we expected that
each model would exhibit fewer amyloid plaques in the absence of
ABCA1. However, despite a large reduction in apoE levels, amyloid
burden was not diminished in either model. Our results support the
hypothesis thatABCA1hasminimal impact onA levels in vivo but that
ABCA1-mediated effects on lipidation and levels of apoE may partici-
pate in the conversion of A from soluble peptides to insoluble amyloid.
EXPERIMENTAL PROCEDURES
MouseModels—ABCA1-deficient mice were generously provided by
Dr. Omar Francone (Pfizer Global Research andDevelopment (Groton,
CT)) and are on a DBA/1LacJ genetic background (63). Tg-SwDI/B
mice express the human APP770 cDNA containing the Swedish
(K670M/N671L), Dutch (E693Q), and Iowa (D694N)mutations and are
on a congenic C57Bl/6 genetic background (64). Neuronally specific
expression is directed from the mouse Thy1.2 promoter. Beginning at
24–30 weeks of age, thioflavine S-positive amyloid deposits are
observed primarily within the cerebrovasculature, as the Dutch and
Iowa mutations alter the charge of the A peptide and promote depo-
sition in cerebral microvessels rather than in the neural parenchyma
(64). The APP/PS1 (line 85) mouse model (The Jackson Laboratories)
co-expresses two transgenes that are each expressed from the mouse
prion promoter. One transgene is a chimeric mouse/human APP650
cDNA containing the Swedish (K670M/N671L) mutations, and the
other is the human presenilin 1 (PS1) gene containing theE9 (deletion
of exon 9) mutation (65). Both transgenes are inserted at a single locus
and are inherited together. The level of transgenicAPP expression in the
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APP/PS1 mice is estimated to be 2–4-fold over murine APP levels
(65). The APP/PS1 mice are maintained on a mixed F1 C3H/H3J 
C57Bl/6 genetic background and develop parenchymal thioflavine
S-positive amyloid deposits at 36–40 weeks of age (65). All animals
were maintained on a standard chow diet (PMI LabDiet 5010, contain-
ing 24% protein, 5.1% fat, and 0.03% cholesterol). All procedures involv-
ing experimental animals were performed in accordance with protocols
from theCanadianCouncil of Animal Care and theUniversity of British
Columbia Committee on Animal Care.
Tissue Collection—Mice were anesthetized with a mixture of 20
mg/kg xylazine (Bayer) and 150 mg/kg ketamine (Bimeda-MTC) and
transcardially perfused with phosphate-buffered saline (PBS) for 7 min.
Brains were removed and divided into right and left hemispheres. Cor-
tex and hippocampus were dissected from the right hemisphere and
kept frozen at 80 °C until analysis. The left hemisphere was immer-
sion-fixed in 10% neutral buffered formalin for at least 48 h and cryo-
protected in 30% sucrose in PBS at 4 °C.
Protein Extraction from Brain Tissue—Protein extractions from cor-
tical and hippocampal regions were done in three consecutive steps in
order to evaluate apoE, ABCA1, APP, and A levels from the same
animals. Brain regions were homogenized in 8 volumes of ice-cold
PBS containingComplete protease inhibitor (RocheApplied Science) in
a Tissuemite homogenizer. The homogenate was centrifuged at 4 °C for
45 min at 12,500 rpm in a microcentrifuge (Eppendorf). The superna-
tant (soluble fraction) was removed and used to evaluate soluble apoE.
No ABCA1 or APP was detectable in this fraction, as both are mem-
FIGURE 1. Presence of the APP transgene does
not modify ABCA1 abundance. ABCA1 protein
levels in the hippocampus of Tg-SwDI/B (A) and
APP/PS1 (B) mice were determined by Western
blot and quantitated by densitometry. Graphs are
expressed as % of wild-type (APP, ABCA1/
mice were assigned 100%) and illustrate at least
two independent experiments.A,data correspond
to four individual mice per genotype (2F and 2M).
B, data represent APP, ABCA1/ (n 5 (3F and
2M); APP, ABCA1/ (n 5 (2F and 3M)); APP,
ABCA1/ (n 6 (3F and 3M)); APP, ABCA1/
(n  6 (2F and 4M)); APP, ABCA1/ (n  5 (2F
and 3M)); and APP, ABCA1/ (n  5 (2F and
3M)). Western blots show two representative sam-
ples per group. GAPDH was used as an internal
loading control. ** represents p 0.001 compared
with wild-type (APP-ABCA1/) by ANOVA with
Newman-Keuls post-test.
Absence of ABCA1 Affects Amyloidosis
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brane-bound proteins. The pellets from the PBS solubilization stepwere
then resuspended in ice-cold lysis buffer (containing 10% glycerol, 1%
Triton X-100, and Complete protease inhibitor (Roche Applied Sci-
ence) in PBS) and centrifuged at 4 °C for 10min at 9,000 rpm in order to
extract ABCA1 and APP. The pellet from this step (insoluble fraction)
was finally solubilized in 5 M guanidine hydrochloride in 50 mM Tris-
HCl, pH 8.0, at room temperature for about 2.5–3 h with continuous
rotation in order to evaluate plaque-associated A and apoE. Brain tis-
sue from all animals was extracted in the identical manner, and all frac-
tions were immediately frozen at80 °C until analysis. Protein concen-
trations were determined by DC Protein Assay (Bio-Rad).
Western Blotting—ApoE, ABCA1, and APP levels were determined
by Western blot. For soluble apoE (PBS fraction), ABCA1, and APP
(lysis buffer fractions), protein concentrations were determined by DC
protein assay (Bio-Rad) prior to analysis. Equal amounts of protein were
electrophoresed through 10% SDS-polyacrylamide gels, electrophoreti-
cally transferred to polyvinylidene fluoride membrane (Millipore), and
immunodetected using a murine-specific apoE antibody (Santa Cruz
Biotechnology), a monoclonal anti-ABCA1 antibody raised against the
second nucleotide binding domain (48), 22C11, which detects both
murine and human APP (Chemicon), or an anti-GAPDH antibody
(Chemicon) as a loading control. Blots were developed using enhanced
chemiluminescence (Amersham Biosciences) according to the manu-
facturer’s recommendations. For insoluble apoE, protein loading was
normalized by Coomassie Blue staining of duplicate gels. Bands were
quantitated by densitometry using NIH Image J software.
A Measurements—Human A levels were quantified by ELISA
(BIOSOURCE) according to themanufacturer’s protocol. Sampleswere
analyzed diluted in reaction buffer as described in the manufacturer’s
protocol. Endogenous murine A40 levels were quantified using 75 g
of protein from total hippocampal homogenates. The coating antibody
used was R163 (66, 67) for A40 (a generous gift from Dr. P. D. Mehta,
New York Institute for Basic Research, Staten Island, NY). Plates were
coated overnight at 4 °C and then blocked with PBS containing 0.1%
bovine serum albumin for 2 h at room temperature. Following five
washes with TBS-T (Tris-buffered saline containing 0.1% Tween 20),
samples were incubated for 2 h at room temperature with biotinylated
4G8 (Signet Laboratories Inc., Dedham, MA) for 1 h at room tempera-
ture with agitation. The plates were washed five times, and streptavidin-
alkaline phosphatase complex was added for 1 h at room temperature.
Plates were finally washed five times with TBS-T and once with water,
and AttoPhos reagent (Calbiochem) was added for 30–60 min, and a
reading was taken on a Bio-Tek FL600 fluorescence microplate reader.
Human andmurine A levels were normalized to total protein asmeas-
ured by DC Protein Assay (Bio-Rad).
Histological Analysis—25-m-thick, coronal sections were cut on
fixed brains using a cryostat from the genu of the corpus callosum to the
most caudal hippocampus. For thioflavine S staining, sections were
immersed for 10 min in 1% thioflavine S solution followed by washing
and dehydration in increasing ethanol concentrations from 70 to 100%
followed by xylene. Slides were mounted in dibutyl phthalate xylene
mounting medium (DBH) and visualized within the following 24 h. A
immunohistochemistry was performed as reported previously (68) with
slight modifications. Briefly, floating sections were incubated in 88%
formic acid for 5 min, incubated for 30 min with 0.3% H2O2 in PBS-T
(0.01 M PBS, pH 7.4, containing 0.3% Triton X-100), transferred into 1%
horse serum (Vector Laboratories) in PBS-T for 30 min, and incubated
overnight at 4 °C in 1.5% horse serum in PBS-T containing antibodies
4G8 and 6E10 (Chemicon) (1:1000 dilution each) against residues
17–24 and 1–17 of A, respectively. Sections were then washed with
PBS-T, treated for 1 h at room temperature with a biotinylated anti-
mouse antibody (1:1000, Vector Laboratories), and followed by incuba-
tion in avidin-biotinylated horseradish peroxidase complex (ABC Elite,
Vector Laboratories; 1:1000) for 1 h at room temperature. Peroxidase
labeling was visualized by incubation in 0.05% 3,3-diaminobenzidine
(Sigma) and 0.001% H2O2 in 0.05 M Tris-HCl buffer, pH 7.6. After a
2-min incubation period, sections were washed, mounted on glass
slides, and coverslipped with dibutyl phthalate xylene mounting
medium. Imaging was performed on a Zeiss Axioplan 2 microscope
using Metamorph capture software.
QuantitativeAnalysis of Amyloid andABurden—Amyloid loadwas
quantitated in different brain regions depending on the mouse model.
For the hippocampus (Tg-SwDI/B and APP/PS1), six sections, 300 m
apart and spanning the entire length of the hippocampus, were chosen
for staining and subsequent analysis. For the thalamus (Tg-SwDI/B),
FIGURE 2. APP levels are unaffected in the absence of ABCA1. APP protein levels in
hippocampus of Tg-SwDI/Bmice (A) and cortex of APP/PS1mice (B) were determined by
Western blot and quantitated by densitometry. Graphs are expressed as % of wild-type
(APP, ABCA1/ mice were assigned 100%) and illustrate at least two independent
experiments. A, data correspond to four individual mice per genotype (2F and 2M). B,
data represent four individual mice per genotype (2F and 2M). Western blots show two
representative samples per group. GAPDH was used as an internal loading control.
* represents p  0.01 and ** represents p  0.001 compared with wild-type (APP,
ABCA1/) by ANOVA with Newman-Keuls post-test.
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four sections, 300 m apart, starting at the most rostral aspect of the
thalamuswere chosen.Quantification of amyloid in the cingulate cortex
(APP/PS1) was performed on sections before the emergence of the genu
of the corpus callosum on a total four sections, 300 m apart. This
systematic sampling strategy was chosen to account for subregional
variations of hippocampal size and potential subregional variations in
plaque burden. The slides were viewed in a Zeiss Axioplan 2microscope
under light of wavelength 450–490 nm. Colored images were captured
using Metamorph software and a Cool Snap HQ camera (Photomet-
rics). Camera settings were adjusted at the start of the experiment and
maintained for uniformity. Using Metamorph software, low magnifica-
tion (2.5) images were acquired. A computer-generated grid com-
posed of 16 higher magnification (10) fields was superimposed on
each2.5 image. Throughout the hippocampus, 50% of the10 fields
was randomly selected, and images of these fields were acquired for
analysis. Areas of the regions of interest in each 10 image were out-
lined manually. The plaque/amyloid area within the fields of interest
was identified by color and intensity-level threshold, the level of which
was maintained throughout the experiment. After manual editing of
staining artifacts, the thresholded and total areas, the amyloid load
defined as (sumof thioflavine S staining areameasured/sumof field area
analyzed)  100 was calculated for each mouse. Images were quanti-
tated by raters blinded to genotype.
For A load, stained sections were chosen using the same sampling
method using sections cut immediately before or after those stained
with thioflavine S. Gray scale images were captured and analyzed as
above. TheA load was defined as the (sum of A immunoreactive area
measured/sum of field area analyzed)  100 and was determined by
raters blinded to genotype.
The number of thioflavine S ve plaques per unit area was also cal-
culated for hippocampus and a larger cortical area in the APP/PS1mice.
For this procedure, plaques visible on 2.5x images were counted manu-
ally by raters blinded to genotype. The boundaries of the hippocampus
were used, whereas limits of the larger cortical area were determined by
transecting each image with a horizontal line through the corpus callo-
sum and counting all thioflavine S positive plaques above this line.
Plaque count totals were averaged between two independent raters
blinded for genotype, corrected for total area, and expressed as the
number of thioflavine Sve plaques/m2.
Statistical Analysis—Data are shown as means  S.E. One-way
ANOVA with a Newman-Keuls post-test or two-tailed unpaired Stu-
dent’s t tests were used for statistical analysis. In the t test analyses,
FIGURE 3. Soluble A levels are not affected by
lack of ABCA1. Soluble A40 levels in Tg-SwDI/B
hippocampi were quantitated from PBS (A) and
lysis buffer (B) extracts. SolubleA40 levels inAPP/
PS1 cortex were quantitated from the PBS (C) and
lysis buffer (D) extracts. ELISA values were normal-
ized to total protein as determined by DC protein
assay. Graphs correspond to Tg-SwDI/B,
ABCA1/ (n  8 (4F and 4M) and Tg-SwDI/B,
ABCA1/ (n  8 (4F and 4M)) (A and B) and to
APP, ABCA1/ (n 6 (2F and 4M)) and APP,
ABCA1/ (n 7 (3F and 4M)) (C and D). Endoge-
nous murine A40 levels in hippocampus (E) and
cortex (F) were determined by ELISA in ABCA1/
(n  11 (6F and 5M)), ABCA1/ (n  12 (6F and
6M)), and ABCA1/ (n  10 (6F and 4M)) mice.
Values were normalized to total protein.
Absence of ABCA1 Affects Amyloidosis
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Welch’s correction for unequal variances was applied when variances
were significantly different between groups. All statistical analyses were
performed using Graphpad Prism (version 4.0; Graphpad software for
Science Inc., San Diego).
RESULTS
ABCA1 Levels Are Unaffected by the APP and PS1 Transgenes—To
evaluate whether the presence of an APP or PS1 transgene affected
ABCA1 expression, we first determined ABCA1 protein levels in the
hippocampus and cortex in twomouse models of AD. Tg-SwDI/Bmice
express human APP containing the Dutch (E693Q) and Iowa (D694N)
mutations in neurons under the control of the mouse Thy1 promoter
(64). APP/PS1 mice use the murine prion promoter to co-express a
chimeric mouse/human APP650 cDNA containing the Swedish
(K670M/N671L) mutations, as well as the human PS1 gene containing
the E9 mutation (65). Tg-SwDI/B animals were examined at 10
months of age and contained abundant ABCA1 protein in wild-type
mice and no detectable ABCA1 in ABCA1/mice (Fig. 1A). No effect
of the APP transgene onABCA1 levels was observed (Fig. 1A). APP/PS1
mice were examined at 12 months of age. As expected, ABCA1 levels
were undetectable in the hippocampus of ABCA1/ mice and were
reduced by 60% in ABCA1/ mice compared with wild-type con-
FIGURE4.Guanidine-extractableA levels are independentofABCA1genotype.A40andA42 levels in hippocampusof Tg-SwDI/B (A andB, respectively) and inhippocampus
(C and D) and cortex (E and F) of APP/PS1 mice were measured by ELISA. Values were normalized to total protein as determined by DC protein assay. Graphs correspond to
Tg-SwDI/B, ABCA1/ (n 14 (8F and 6M) and Tg-SwDI/B, ABCA1/ (n 8 (4F and 4M)) (A and B) and to APP, ABCA1/ (n 6 (2F and 4M)), APP, ABCA1/ (n at least
4 (2F and 2M)), and APP, ABCA1/ (n 7 (3F and 4M)) (C–F).
Absence of ABCA1 Affects Amyloidosis
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trols irrespective of the presence of the APP or PS1 transgenes (Fig. 1B).
Similar results were observed in the cortex of APP/PS1 mice (data not
shown).
Deficiency of ABCA1 Does Not Affect APP or A Levels in Vivo—
Western blots of brain lysates were then used to determine whether
deficiency of ABCA1 affected APP expression in vivo. As expected, total
APP levels were significantly higher in lysates of transgenic Tg-SwDI/B
(Fig. 2A) and APP/PS1 (Fig. 2B) brains compared with nontransgenic
controls. APP protein levels were identical in wild-type, heterozygous,
and ABCA1-deficient mice in both Tg-SwDI/B and APP/PS1 models
(Fig. 2, A and B), demonstrating that ABCA1 does not influence APP
abundance. In contrast to the reported 50% increase in APP levels over
endogenous levels in the Tg-SwDI/B model (64), we observed that
transgenic mice expressed 2–3-fold more APP than controls in our
cohorts. Possible explanations for this discrepancy include different
protein extraction protocols and the different genetic background of the
animals upon breeding to ABCA1 hemizygous mice.
Because ABCA1 has been reported previously to either increase (59)
or decrease (51, 58) A production in cultured cells, we next evaluated
whether ABCA1 affected the steady-state levels of human A in the
brains of Tg-SwDI/B and APP/PS1 mice with various ABCA1 gene
doses. Several serial extraction protocols have been developed to
remove different A pools from brain tissue. We developed an extrac-
tion protocol to allow the levels of A to be determined from the same
brain samples that were used to measure ABCA1, APP, and apoE pro-
tein levels. Brainswere first extracted in PBS and then in lysis buffer, and
soluble and weakly membrane-associated A was measured from each
fraction. No significant differences in A40 levels were observed in
either fraction from either model (Fig. 3, A–D). PBS-soluble and lysis
buffer-soluble A42 levels were below the detection limit of our assay
(data not shown).We also evaluated the impact of ABCA1 deficiency on
steady-state levels of endogenousmurine A40 in the parental ABCA1-
deficient mice, and we found that murine A40 levels were indistin-
guishable among wild-type, heterozygous, and ABCA1-deficient mice
in the cortex and hippocampus (Fig. 3, E and F). These results demon-
strate that the abundance of soluble A species is not elevated in the
absence of ABCA1.
To facilitate comparison of insoluble A levels in our studies to sev-
eral other relevant publications (39, 69, 70), we elected to use 5 M gua-
nidine to extract A that is likely to be strongly associated with mem-
branes or deposited within plaques. No significant differences were
observed in steady-state guanidine-extractable A40 or A42 levels in
either model (Fig. 4). These data are summarized in TABLE ONE and
suggest that deletion of ABCA1 has no significant impact on either
transgenic or endogenous steady-state A levels in vivo.
ABCA1 Deficiency Increases A Deposition in Tg-SwDI/B Mice—To
evaluate the pattern and quantity of A deposits, hemicoronal sections
of Tg-SwDI/B and APP/PS1 brains were stained for A deposits as
described. In 10-month-old Tg-SwDI/B mice, there was a significant
2-fold increase in A immunoreactivity in the absence of ABCA1 com-
pared with controls (TABLE ONE), and the staining distribution pat-
tern was indistinguishable between groups (Fig. 5). Most A immuno-
reactivity in the hippocampus was observed in the subiculum and the
polymorph layer of the dentate gyrus (Fig. 5A). In 12-month-old APP/
PS1 mice, no significant differences in the distribution pattern or quan-
tity of A deposits were noted in the hippocampus of ABCA1-deficient
animals compared with wild-type littermate controls (Fig. 5B and
TABLE ONE). Deposits were observed throughout the hippocampus
and cortex of APP/PS1 animals.
Deficiency of ABCA1 Reduces Soluble ApoE Levels in Vivo—We and
others have shown previously that ABCA1 is required to maintain nor-
mal levels of apoE in the central nervous system (42, 43). Western blots
were used to determine whether PBS-extractable apoE levels were
decreased as expected in the presence of the APP or PS1 transgenes. In
10-month-old Tg-SwDI/B mice, PBS-soluble apoE levels were reduced
by 75% in APP/ABCA1/ hippocampus compared with APP/
ABCA1/ controls (p  0.001; Fig. 6A). Similarly, in 12-month-old
APP/PS1 mice, soluble apoE levels were 80% lower in the hippocampus
of mice lacking ABCA1 compared with animals with wild-type levels of
ABCA1 (Fig. 6B). Mice with heterozygous levels of ABCA1 had normal
levels of soluble apoE (Fig. 6B). Similar results were observed in the
cortex of APP/PS1 mice (data not shown). These observations confirm
our previous results and demonstrate that the influence of ABCA1 on
apoE levels in brain is maintained in the presence of the APP and PS1
transgenes.
ApoE levels have been reported to be elevated in response to
chronic or acute neuronal damage (30–33). We observed elevated
levels of soluble apoE in APP/PS1 transgenic mice compared with
TABLE ONE
A levels, A immunoreactivity, and amyloid load by region andmousemodel in the presence or absence of ABCA1
Hippocampus Cortex
Wild type ABCA1/ Wild type ABCA1/
Mean S.D. n Mean S.D. n p value Mean S.D. n Mean S.D. n p value
TgSwDI/B
A40 (pg/mg) 54626 13991 14 58701 29958 8 NSa NDb ND
A42 (pg/mg) 288.9 189 14 221.9 262.8 8 NS ND ND
A load (%) 0.1 0.063 8 0.26 0.169 8 0.05 ND ND
Amyloid load (%) 0.076 0.058 8 0.255 0.125 8 0.005 ND ND
APP/PS1
A40 (ng/mg) 99.25 76.74 6 159.3 99.11 7 NS 179.2 94.87 6 222.5 91.66 7 NS
A42 (ng/mg) 172.7 82.4 6 203 65.95 7 NS 470.2 89.6 6 529.7 172.8 7 NS
A load (%) 1.56 0.97 4 0.79 0.38 5 NS ND ND
Amyloid load (%) 0.62 0.35 6 0.73 0.44 7 NS 1.16 0.55 6 0.99 0.26 7 NS
Plaque no. (plaques/m2) 1.71e-05 1.00e-05 6 2.54e-05 1.33e-05 7 NS 4.21e-05 1.65e-05 6 4.74e-05 5.74e-06 7 NS
Parental ABCA1/
A40 (ng/g) 0.394 0.137 11 0.445 0.189 10 NS 0.577 0.208 11 0.535 0.179 10 NS
a NS indicates not significant.
b ND indicates not determined.
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nontransgenic controls that contained at least one functional copy of
ABCA1 (Fig. 6B), but we did not observe this effect in Tg-SwDI/B
transgenic mice (Fig. 6A). This could be due to differences in the
degree of AD pathology in each model at the time of assessment,
including less amyloid deposition in Tg-SwDI/B compared with
APP/PS1 mice and different distribution of amyloid, with thioflavine
S ve deposits being mostly parenchymal in the APP/PS1 and vas-
cular in the Tg-SwDI/B animals.
In the APP/PS1 model with extensive A deposition, APP/PS1
transgenic mice with wild-type levels of ABCA1 showed a significant
increase in PBS-extractable apoE in the hippocampus (90%, p 
0.001) compared with ABCA1/ mice lacking the APP/PS1 trans-
genes (Fig. 6B). ABCA1 heterozygous mice carrying the APP/PS1
transgenes also showed a trend toward increased apoE levels in the
hippocampus (30%, p	 0.05) compared with ABCA1/mice lack-
ing the APP and PS1 transgenes (Fig. 6B). Similar results were
observed in the cortex of APP/PS1 mice (data not shown). These
observations suggest that apoE expression is induced in mice with
abundant A deposition, consistent with a role for apoE in mitigat-
ing neuronal damage. Notably, apoE failed to be induced in the
absence of ABCA1 in either model, suggesting that ABCA1 is
required to observe the increase in apoE secretion under conditions
of neuronal stress.
Deficiency of ABCA1 Increases Amyloid Deposition in Tg-SwDI/B
Mice—In both Tg-SwDI/B andAPP/PS1models, guanidine-extractable
A levels were unchanged in the absence of ABCA1, suggesting that
ABCA1 has minimal impact on the steady-state levels of A. Further-
more, both models exhibited a robust decrease in soluble apoE levels.
Based on these observations, we expected to observe less amyloid dep-
osition inABCA1-deficientmice, consistent with previous observations
that the level of apoE is a key determinant of amyloid deposition in
murine models (36, 71). However, contrary to our expectations of
reduced amyloid burden, quantitative stereological assessment of amy-
loid in the hippocampus of 10-month-old Tg-SwDI/B mice revealed a
significant 2-fold increase of amyloid in the absence of ABCA1, partic-
ularly in the subiculum and polymorph layer of the dentate gyrus (p
0.02) (Fig. 7A and TABLE ONE). Deposits in the subiculum were
observed to be mostly vascular, whereas the deposits in the dentate
gyrus were predominantly parenchymal. These observations are con-
FIGURE 5.Absence of ABCA1 does not alter A distribution and elevates A load in
Tg-SwDI/B mice. Immunohistochemistry for A was performed as described in
Tg-SwDI/B, ABCA1/ (n 8 (4F and 4M)) and Tg-SwDI/B, ABCA1/ (n 8 (4F and
4M)) (A) and in APP, ABCA1/ (n 4 (1F and 3M)), APP, ABCA1/ (n 5 (2F and
3M)), and APP, ABCA1/ (n  5 (2F and 3M)) (B) brains. Pictures correspond to two
representativemiceper genotype at2.5magnification. Insets correspond to40mag-
nification of individual plaques. A, scale bars represent 1000 m (large hippocampal
image) and40m(inset).B, scale bars represent1000m(large image) and60m(inset).
FIGURE 6.ABCA1 deficiency decreases soluble apoE levels in cortex and hippocam-
pus. PBS-extractable apoE levels were determined by Western blot in hippocampus of
Tg-SwDI/B (A) and APP/PS1 (B) mice and quantitated by densitometry. Graphs are
expressed as % of wild-type (APP-ABCA1/mice were assigned 100%) and illustrate at
least two independent experiments.A,data correspond to eight individualmice for each
genotype (4F and 4M). B, data represent APP, ABCA1/ (n 6 (3F and 3M)), APP,
ABCA1/ (n 5 (2F and 3M)), APP, ABCA1/ (n 6 (3F and 3M)), APP, ABCA1/
(n 6 (2F and 4M)), APP, ABCA1/ (n 4 (2F and 2M)), and APP, ABCA1/ (n 5
(2F and 3M)) mice. Western blots show two representative samples per group. GAPDH
wasused as an internal loading control. ** representsp0.001 comparedwithwild-type
(APP, ABCA1/) control and # represents p  0.001 compared with nontransgenic
animals by ANOVA with Newman-Keuls post-test.
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sistent with an increase in deposited A in Tg-SwDI/B mice that lack
ABCA1. We also examined the impact of ABCA1 on amyloid deposits
in the thalamus, which is a heavily vascularized region. Thalamic amy-
loid deposits were also significantly increased by 2-fold in the absence of
ABCA1 (p 0.005; Fig. 7B). Vascular deposits involved larger vessels in
ABCA1 deficient mice compared with wild-type controls.
Amyloid Burden Is Not Diminished Despite Reduced ApoE Levels in
APP/PS1 Mice—Amyloid deposition was also assessed in the hip-
pocampus and cortex of APP/PS1 mice between 12 and 13 months of
age, a time in disease progression characterized by abundant amyloid
deposits in this model. Again, contrary to our expectations of reduced
amyloid due to lower apoE levels, amyloid burden was not significantly
diminished in either the hippocampus (Fig. 8, A and B, and TABLE
ONE) or cortex (Fig. 8, C and D, and TABLE ONE) of wild-type, het-
erozygous, and ABCA1-deficient mice. These findings are consistent
with no significant change in A deposits in APP/PS1 mice that lack
ABCA1. However, unlike the Tg-SwDI/Bmodel, we observed that dele-
tion of ABCA1 resulted in no significant increase in amyloid burden or
distribution in APP/PS1 mice when quantitated either by fluorescence
threshold per area (Fig. 8 and TABLE ONE) or by plaque number per
unit area (TABLE ONE).
ABCA1 Regulates ApoE Solubility in Brain—Previous studies have
shown that insoluble, non-PBS-extractable apoE appears in transgenic
AD mice during the development of amyloid plaques (72), suggesting
that apoE becomes sequestered within plaques and is removed from the
soluble pool. To determine whether the absence of ABCA1 affected this
insoluble pool of apoE, we analyzed the guanidine-extractable pool of
apoE by Western blot.
In Tg-SwDI/Bmice, guanidine-soluble apoE levels were reduced only
by 50% in the hippocampus of ABCA1-deficient mice compared with
mice with wild-type levels of ABCA1 (p  0.01; Fig. 9). Because defi-
ciency of ABCA1 resulted in a 75% reduction in soluble apoE levels,
these observations suggest apoE may be beginning to be sequestered in
amyloid plaques at this stage in pathogenesis.
In APP/PS1mice with abundant plaques, we observed a clear ABCA1
dose-dependent increase in insoluble apoE levels in both hippocampus
and cortex (Fig. 10). Compared with mice with wild-type levels of
ABCA1, insoluble apoE was elevated by 63% (p 	 0.05) in the hip-
pocampus and by 175% (p	 0.05) in the cortex inABCA1/ compared
with ABCA1/ mice (Fig. 10, A and B, respectively). This increase in
insoluble apoE was even more dramatic in the complete absence of
ABCA1 (Fig. 10, A and B), with a 2-fold increase observed in both the
hippocampus and cortex (p 0.01).
These observations demonstrate that ABCA1 has a marked effect on
the distribution of apoE in the brain. In the Tg-SwDI/B model, the lack
of ABCA1 decreases the proportion of insoluble apoE in parallel with
the decrease in soluble apoE. However, the decrease in the insoluble
fraction of apoE is less than expected. In the APP/PS1 model, lack of
ABCA1 results in a dramatic increase in the proportion of apoE found in
the insoluble fraction. This observation suggests that absence ofABCA1
shifts the distribution of apoE from soluble to insoluble pools during the
formation of amyloid plaques in vivo.
DISCUSSION
Much of the current research supports a role for cholesterol in AD
(19, 73), suggesting that genes that regulate cholesterolmetabolismmay
influence the pathogenesis of AD. The cholesterol and phospholipid
transporter ABCA1 is a critical regulator of HDLmetabolism in periph-
eral tissues, and is expressed in the brain where it has been shown
recently to regulate apoE levels (42, 43). ABCA1 has also been impli-
FIGURE 7.Absence of ABCA1 increases amyloid deposition in Tg-SwDI/Bmice. Thioflavine S staining of hemicoronal sections from Tg-SwDI/B hippocampus (A) and thalamus (B)
in the presence and absence of ABCA1. Pictures show two individual mice per genotype and correspond to2.5 images for the hippocampus (A) and10 images for thalamus (B).
Scale bars represent 1000 m in A and 250 m in B. Arrows point toward vessels. Amyloid load was quantitated as described under “Experimental Procedures” in Tg-SwDI/B,
ABCA1/ (n 7 (3F and 4M)) and Tg-SwDI/B, ABCA1/ (n 8 (4F and 4M)) mice. Student’s t test was used for statistical analysis.
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cated in A metabolism, and genetic studies suggest that polymor-
phisms in ABCA1may be associated with AD (74–76). These observa-
tions indicate that ABCA1 may be a gene of interest for AD, although
whether ABCA1 influences AD neuropathology in vivo and whether
this occurs through effects onA or apoEmetabolism have not yet been
addressed. We and Koldamova et al. (92) and Wahrle et al. (93) now
report in vivo studies supporting a prominent role for ABCA1 in
amyloidogenesis.
In this study, we investigated the impact of ABCA1 deficiency on
steady-state A levels, amyloid burden, and apoE abundance and dis-
tribution in the Tg-SwDI/B and APP/PS1 murine models of AD. Three
major conclusions can be drawn from our study. First, the absence of
ABCA1 did not significantly affect the levels of soluble or insoluble A
when crossed to either Tg-SwDI/B or APP/PS1mice, nor did it alter the
levels of endogenous murine A in the parental ABCA1-deficient ani-
mals. These observations suggest that ABCA1may not play amajor role
in A production in vivo. Second, ABCA1 is required to maintain apoE
levels in vivo. This was shown previously in the parental ABCA1/
mice (42, 43) and is here confirmed upon breeding ABCA1-deficient
mice to either the Tg-SwDI/B or APP/PS1 models. This observation
suggests that the effect of glial ABCA1 on secretion of apoE from astro-
cytes and microglia remains similar across a variety of genetic back-
grounds and in the presence of APP and PS1 transgenes. Third, and in
contrast to our expectations, the ABCA1-mediated decrease of apoE
levels failed to reduce amyloid and A deposition in both the
Tg-SwDI/B and APP/PS1 models. Based on the lack of effect of ABCA1
onA levels but the pronounced effect of ABCA1 on apoE levels in vivo,
we predicted amyloid deposition would be decreased in the absence of
ABCA1, in line with previous observations that apoE levels determine
the extent of amyloid deposition in vivo (36–39). In contrast, we
observed more extensive parenchymal and vascular A deposition and
significantly elevated amyloid burden in theTg-SwDI/Bmodel despite a
75% reduction in apoE levels. In the APP/PS1model, we again observed
no decrease in amyloid burden despite an 80% decrease in soluble apoE
levels in the absence of ABCA1.
One possible explanation for this relates to the role of apoE in A
clearance. Several studies have shown that apoE bindsA and suggested
that this interaction might aid in the clearance of A (77–80). Further-
more, two recent studies have shown that astrocytes are capable of
clearing A deposits from brain slices of aged APP transgenic mice (81,
82) and that this process is apoE-dependent (82). Together, these obser-
vations suggest that apoE is a key factor in regulating A clearance in
vivo. It is plausible to hypothesize that the low levels of apoE that exist in
the brains of ABCA1-deficient mice are sufficient to allow for amyloid
formation but are not enough to mediate effective A clearance.
It is also possible that the poor lipidation of apoE in the absence of
ABCA1 renders apoE prone to sequestration in amyloid plaques and
enhances the conversion of A from soluble peptides into amyloid. This
hypothesis is supported by our observation that ABCA1 markedly
affects the distribution of apoE in soluble compared with insoluble
pools. In the Tg-SwDI/B model, ABCA1 deficiency reduced soluble
apoE levels by 75% but reduced insoluble apoE levels only by 50% com-
FIGURE 8. Absence of ABCA1 does not diminish amyloid burden in APP/PS1 mice. A, thioflavine S staining of hemicoronal sections from APP/PS1 mice in the presence and
absenceofABCA1. Scale bars represent 1000m.B, amyloid loadwasquantitated in thehippocampus (B) and cingulate cortex (C) as describedunder “Experimental Procedures.” The
graph corresponds to APP/PS1, ABCA1/ (n  6 (2F and 4M)), APP/PS1, ABCA1/ (n  5 (2F and 3M)), and APP/PS1, ABCA1/ (n  7 (3F and 4M)) mice. No significant
differences were found by ANOVA.
Absence of ABCA1 Affects Amyloidosis
43252 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280•NUMBER 52•DECEMBER 30, 2005
 by guest, on January 19, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
pared with mice with ABCA1. In the APP/PS1 model, soluble apoE was
decreased by 80%, but apoE extracted from the insoluble fraction was
elevated 2-fold in ABCA1/ compared with ABCA1/mice.Wahrle
et al. (93) also observed increased levels of guanidine-extractable insol-
uble apoE in transgenic PDAPP mice.
One limitation of our study is that the Western blot methodology
used in our experiments does not allow us to quantitate accurately the
relative proportion of insoluble compared with soluble apoE. Further-
more, the two AD models used in this study cannot be directly com-
pared, due primarily to differences in the stage of disease pathogenesis
and A properties. Although the Tg-SwDI/B and APP/PS1 mice were
examined at similar ages, theAPP/PS1model exhibited a 10-fold greater
amyloid burden at the time of analysis compared with the Tg-SwDI/B
animals. Additionally, Tg-SwDI/B mice express a human A carrying
the Dutch and Iowa mutations that may affect APP processing and
influence the mechanism of A deposition, whereas the APP/PS1
model generates wild-type human A. These important differences in
A species in these two models could potentially alter binding to and
deposition/clearance with apoE. Nevertheless, our observation that
nearly all detectable apoE was present in the insoluble fraction in the
APP/PS1 model raises the possibility that apoE continues to be
recruited to amyloid plaques after they are seeded, and that the poorly
lipidated apoE present in the brains of ABCA1/ mice may either be
recruitedmore effectively to amyloid deposits or is unable to clear these
deposits as efficiently as normally lipidated apoE.
One of the strengths of this study is that we used two independent
models of AD with different transgenes, promoters, and genetic back-
grounds. The conclusions that the deficiency of ABCA1 has no effect on
soluble or guanidine-extractable steady-state A levels but significantly
decreases apoE levels and fails to diminish amyloid burden are consist-
ent in both these models, despite the important differences in A spe-
cies generated in the Tg-SwDI/B compared with APP/PS1 mice. Our
major conclusions that deficiency of ABCA1 is associated with low lev-
els of apoE, a shift in the distribution of apoE from soluble to insoluble
pools, and either no change or increased deposition of fibrillar A are
also similar to those of Koldamova et al. (92) and Wahrle et al. (93). By
using APP23 mice, Koldamova et al. (92) report that the absence of
ABCA1 results in significantly decreased apoE levels, significantly
increased formic acid-extractable A levels, and significantly increased
parenchymal and vascular amyloid deposition. By using the PDAPP
model, Wahrle et al. (93) observed that deficiency of ABCA1 leads to
significantly elevated guanidine-extractable A levels, a trend toward
increased parenchymal and vascular deposition of A and apoE, and a
dramatic shift of apoE distribution from the soluble to the guanidine-
extractable fraction. Taken together, three laboratories have now inde-
pendently demonstrated that amyloid deposition fails to be reduced in
fourmodels of ADdespite low apoE levels in the absence ofABCA1, and
that these effects extend across differences in the transgene expressed,
themutations it carries, the promoter used, and the genetic background
of the animals.
One difference among the three studies is in the effect of ABCA1 on
A levels. Koldamova et al. (92) found that lack of ABCA1 led to a trend
toward increased soluble A and a significant elevation of insoluble A
extracted using formic acid. Similarly, Wahrle et al. (93) report that the
levels of soluble and guanidine-extractable A are elevated in the
absence of ABCA1. By using a different human-specific ELISA, we
observed no differences in either soluble or guanidine-extractable A
levels between ABCA1-deficient and wild-type brains from either the
Tg-SwDI/B or APP/PS1models. It is possible that the guanidine extrac-
tion protocol used in our study may have failed to quantitatively extract
some of the highly aggregated A sequestered in plaques compared
with formic acid extracts (83). Additionally, compared with the wild-
type humanA generated in theAPP/PS1model, themutations present
in the A of Tg-SwDI/B mice might interfere with its detection by
ELISA, lowering the sensitivity of the test and obscuring possible
increases in the insoluble fraction of A. Differences in A detection
properties might also help to explain why we observed more deposited
A using immunohistochemistry in ABCA1-deficient Tg-SwDI/Bmice
compared with controls, yet did not detect elevated A levels by ELISA.
A second difference among the studies relates to the proportion of
FIGURE 9. ABCA1-deficient Tg-SwDI/B mice have
more insoluble apoE than expected. Guanidine-
soluble apoE levels were determined by Western
blot in thehippocampusof Tg-SwDI/B, ABCA1/
(n 6 (3F and 3M)), Tg-SwDI/B, ABCA1/ (n 9
(5Fand4M)), Tg-SwDI/B, ABCA1/ (n6 (3Fand
3M)), and Tg-SwDI/B, ABCA1/ (n  8 (4F and
4M)) mice and quantitated by densitometry. Coo-
massie Blue staining of parallel gelswas used to nor-
malizeforprotein loading.Graphsareexpressedas%
of APP, ABCA1/ (these samples were assigned
to 100%) and illustrate four independent experi-
ments.Westernblots showrepresentativesamples. *
represents p  0.01 compared with transgenic
ABCA1 wild-type (APP, ABCA1/) control by
ANOVAwith Newman-Keuls post-test.
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apoE residing in the soluble or insoluble fractions. Koldamova et al. (92)
did not detect elevated levels of insoluble apoE after formic acid extrac-
tion, whereas we andWahrle et al. (93) both observed accumulation of
apoE in the guanidine-extractable fraction. Furthermore, Wahrle et al.
(93) demonstrated that this apoE co-localized with amyloid.
The mechanisms underlying the shift in apoE distribution in soluble
to insoluble fractions remain to be elucidated. The low density lipopro-
tein receptors and low density lipoprotein receptor-related proteins are
the major apoE receptors in the central nervous system (84–86), and
LRP is postulated tomediate clearance ofA-apolipoprotein complexes
(86). Because delipidated apoE binds LRP poorly (85, 87), and because
the lipidation status of apoE also influences its interactions with A (78,
89, 90), it is possible that that the poorly lipidated apoE that exists in the
brains of ABCA1-deficient mice (42, 43) may interact differently with
A, and the resulting complexes may not be efficiently recognized by
LRP. Together, these mechanisms could lead to delayed clearance and
increased deposition of A.
Given the large number of studies demonstrating that intracellular
cholesterol levels influence APP processing, an alternative explanation
of our results is that an increase in A production mediated by choles-
terol-enriched ABCA1-deficient neurons may be precisely balanced by
diminished A and amyloid deposition resulting from ABCA1-medi-
ated reductions in apoE levels. Because we observed no change in A
levels in our study, we did not measure A production directly by test-
ing for changes in APP CTF levels. Notably, despite detecting an
increase in A levels, A production was observed to be unaffected in
the absence of ABCA1 in the APP23 and PDAPPmodels (92, 93). How-
ever, because our study, as well as those of Koldamova et al. (92) and
Wahrle et al. (93), used total ABCA1-deficient mice, elucidating the in
vivo impact of ABCA1 on A production independently of its effect on
glia-derived lipoprotein homeostasis will require additional investiga-
tions in neuronal and glia-specific ABCA1 knock-out mice.
Whether the prevalence of AD is increased in Tangier disease
patients that lack ABCA1 has not been specifically addressed, primarily
because Tangier disease is a rare disease and most patients do not sur-
vive past 70 years of age (91). To our knowledge, there is only one case
report of a probandwith a compoundmutation in theABCA1 genewho
developed and died of complications related to CAA (88). Three studies
have investigated whether single nucleotide polymorphisms in the
ABCA1 gene are associated with AD (74–76). Wollmer et al. (74)
reported that the R219K gain-of-function single nucleotide polymor-
phism inABCA1 (R219K) has been suggested to delay the age of onset of
AD by 1.6 years. Katzov et al. (75) reported significant associations with
the R219K, R1587K, and V771M on AD in single marker and haplotype
analyses conducted onEuropean subjects.However, these findingswere
not replicated in a large case-control study of North American subjects
using either single marker or haplotype analyses (76). Further investiga-
tions will therefore be required to determine whether inactivation of
ABCA1 affects AD in humans. Nevertheless, the results of our study,
together with Koldamova et al. (92) andWahrle et al. (93), suggest that
the impact of ABCA1 on ADmay largely be mediated through its effect
on apoE levels and/or lipidation status.
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